Evidence map›Paper›PMID 31708786›Full record

ArticleFrontiers in pharmacology2019

NPC1161B, an 8-Aminoquinoline Analog, Is Metabolized in the Mosquito and Inhibits

Timothy Hamerly, Rebecca E Tweedell, Bernadette Hritzo, Vincent O Nyasembe, Babu L Tekwani, N P Dhammika Nanayakkara, Larry A Walker, Rhoel R Dinglasan

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Synthesis, Biological Studies, andComputational and structural biotechnology journal · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Timothy HamerlyW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.
Rebecca E TweedellW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.
Bernadette HritzoW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.
Vincent O NyasembeDepartment of Infectious Diseases & Immunology, Emerging Pathogens Institute, University of Florida, Gainesville, FL, United States.
Babu L TekwaniDivision of Drug Discovery, Department of Infectious Diseases, Southern Research, Birmingham, AL, United States.
N P Dhammika NanayakkaraNational Center for Natural Products Research, University of Mississippi School of Pharmacy, Oxford, MS, United States.
Larry A WalkerDivision of Drug Discovery, Department of Infectious Diseases, Southern Research, Birmingham, AL, United States.
Rhoel R DinglasanW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.
University of Florida · USJohns Hopkins University · USSouthern Research Institute · USUniversity of Mississippi · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malaria is a major global health threat, with nearly half the world's population at risk of infection. Given the recently described delayed clearance of parasites by artemisinin-combined therapies, new antimalarials are needed to facilitate the global effort toward elimination and eradication. NPC1161 is an 8-aminoquinoline that is derived from primaquine with an improved therapeutic profile compared to the parent compound. The (

Indexed as

8-aminoquinolinemalariametabolite analysisNPC1161BPlasmodiumtransmission-blocking

Identifiers

PMID31708786
PMCPMC6823860
OpenAlexW2981497208

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.